Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 30 | 2024 | 3523 | 2.540 |
Why?
|
Aminoglycosides | 7 | 2017 | 162 | 1.340 |
Why?
|
Core Binding Factors | 2 | 2019 | 31 | 1.060 |
Why?
|
fms-Like Tyrosine Kinase 3 | 8 | 2023 | 491 | 1.050 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 3 | 2024 | 294 | 0.940 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2019 | 776 | 0.780 |
Why?
|
Fanconi Anemia | 1 | 2022 | 319 | 0.710 |
Why?
|
Hematopoietic Stem Cell Transplantation | 8 | 2023 | 5442 | 0.660 |
Why?
|
Gene Rearrangement | 2 | 2021 | 1179 | 0.610 |
Why?
|
Phenylurea Compounds | 3 | 2022 | 528 | 0.590 |
Why?
|
Cytarabine | 6 | 2021 | 692 | 0.590 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2021 | 670 | 0.580 |
Why?
|
Tandem Repeat Sequences | 3 | 2015 | 185 | 0.560 |
Why?
|
Metformin | 1 | 2022 | 835 | 0.510 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 13 | 2021 | 11524 | 0.470 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2012 | 294 | 0.430 |
Why?
|
Niacinamide | 1 | 2015 | 417 | 0.430 |
Why?
|
Antineoplastic Agents | 7 | 2023 | 13695 | 0.420 |
Why?
|
Perceptual Masking | 1 | 2010 | 94 | 0.360 |
Why?
|
Child Language | 1 | 2010 | 64 | 0.360 |
Why?
|
Competitive Behavior | 1 | 2010 | 74 | 0.360 |
Why?
|
Child | 40 | 2023 | 77709 | 0.330 |
Why?
|
Verbal Learning | 1 | 2010 | 467 | 0.310 |
Why?
|
Genes, Wilms Tumor | 3 | 2013 | 94 | 0.300 |
Why?
|
Myelodysplastic Syndromes | 3 | 2022 | 1352 | 0.270 |
Why?
|
Child, Preschool | 24 | 2023 | 41006 | 0.250 |
Why?
|
Phthalimides | 1 | 2024 | 25 | 0.240 |
Why?
|
Piperidones | 1 | 2024 | 28 | 0.240 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 1 | 2023 | 38 | 0.230 |
Why?
|
Mutation | 8 | 2024 | 29786 | 0.230 |
Why?
|
Antigens, CD | 2 | 2012 | 4026 | 0.230 |
Why?
|
Adverse Drug Reaction Reporting Systems | 2 | 2017 | 469 | 0.220 |
Why?
|
Recurrence | 9 | 2022 | 8340 | 0.220 |
Why?
|
Infant | 21 | 2023 | 35136 | 0.220 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2020 | 648 | 0.220 |
Why?
|
Indenes | 1 | 2021 | 57 | 0.190 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2020 | 1519 | 0.190 |
Why?
|
Morpholines | 1 | 2024 | 571 | 0.190 |
Why?
|
Polycythemia | 1 | 2021 | 126 | 0.190 |
Why?
|
Exons | 3 | 2019 | 2437 | 0.180 |
Why?
|
Paraganglioma | 1 | 2021 | 143 | 0.180 |
Why?
|
Leukemia | 2 | 2020 | 1511 | 0.180 |
Why?
|
Adolescent | 26 | 2023 | 85781 | 0.170 |
Why?
|
Remission Induction | 2 | 2022 | 2386 | 0.170 |
Why?
|
Anthracyclines | 1 | 2021 | 288 | 0.170 |
Why?
|
Vidarabine | 1 | 2020 | 345 | 0.160 |
Why?
|
Disease-Free Survival | 8 | 2021 | 6895 | 0.160 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2023 | 689 | 0.160 |
Why?
|
Quinolines | 1 | 2023 | 732 | 0.160 |
Why?
|
Prognosis | 13 | 2023 | 29063 | 0.160 |
Why?
|
Neoplasm, Residual | 3 | 2021 | 973 | 0.160 |
Why?
|
Neoplastic Stem Cells | 1 | 2006 | 1376 | 0.160 |
Why?
|
Treatment Outcome | 21 | 2023 | 63114 | 0.150 |
Why?
|
Cardiotonic Agents | 1 | 2020 | 535 | 0.140 |
Why?
|
Protein Kinase Inhibitors | 3 | 2023 | 5535 | 0.140 |
Why?
|
Leukemia, Myeloid | 2 | 2010 | 707 | 0.140 |
Why?
|
Young Adult | 17 | 2022 | 56430 | 0.140 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2021 | 740 | 0.140 |
Why?
|
Heterocyclic Compounds | 1 | 2017 | 249 | 0.140 |
Why?
|
Azacitidine | 1 | 2017 | 347 | 0.130 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1114 | 0.130 |
Why?
|
Humans | 45 | 2024 | 744343 | 0.120 |
Why?
|
Gene Duplication | 1 | 2015 | 329 | 0.120 |
Why?
|
Infant, Newborn | 10 | 2021 | 25625 | 0.120 |
Why?
|
Central Nervous System Infections | 1 | 2014 | 56 | 0.120 |
Why?
|
Myeloablative Agonists | 1 | 2014 | 218 | 0.120 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2019 | 15519 | 0.110 |
Why?
|
Public Sector | 1 | 2015 | 265 | 0.110 |
Why?
|
Male | 29 | 2021 | 350118 | 0.110 |
Why?
|
Female | 31 | 2021 | 380194 | 0.110 |
Why?
|
Transplantation Conditioning | 2 | 2022 | 1598 | 0.110 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2016 | 329 | 0.100 |
Why?
|
Mycoses | 1 | 2014 | 376 | 0.100 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 2011 | 189 | 0.100 |
Why?
|
Lymphoma | 1 | 2020 | 1877 | 0.100 |
Why?
|
Hematologic Neoplasms | 2 | 2020 | 1832 | 0.090 |
Why?
|
RNA, Messenger | 3 | 2017 | 13033 | 0.090 |
Why?
|
Immunocompromised Host | 1 | 2016 | 847 | 0.090 |
Why?
|
Antifungal Agents | 1 | 2014 | 730 | 0.090 |
Why?
|
Vocabulary | 1 | 2010 | 169 | 0.090 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2013 | 651 | 0.090 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 222 | 0.090 |
Why?
|
Flow Cytometry | 2 | 2020 | 5974 | 0.090 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 7913 | 0.080 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 1 | 2009 | 286 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2727 | 0.080 |
Why?
|
Ventricular Function, Left | 1 | 2020 | 3670 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2016 | 1620 | 0.070 |
Why?
|
Tumor Stem Cell Assay | 1 | 2006 | 118 | 0.070 |
Why?
|
Decision Making | 1 | 2020 | 3887 | 0.070 |
Why?
|
Program Evaluation | 1 | 2015 | 2488 | 0.070 |
Why?
|
Colony-Forming Units Assay | 1 | 2006 | 356 | 0.070 |
Why?
|
Alleles | 3 | 2019 | 6933 | 0.070 |
Why?
|
Etoposide | 2 | 2017 | 641 | 0.070 |
Why?
|
Drug Monitoring | 1 | 2012 | 956 | 0.070 |
Why?
|
Erythroid Precursor Cells | 1 | 2006 | 218 | 0.070 |
Why?
|
Graft vs Host Disease | 2 | 2015 | 2957 | 0.070 |
Why?
|
Retrospective Studies | 10 | 2020 | 77449 | 0.060 |
Why?
|
Antigens, CD34 | 1 | 2006 | 657 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 9239 | 0.060 |
Why?
|
Neutropenia | 1 | 2009 | 895 | 0.060 |
Why?
|
Translocation, Genetic | 1 | 2010 | 1420 | 0.060 |
Why?
|
Risk Factors | 5 | 2021 | 72290 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 5 | 2013 | 6538 | 0.060 |
Why?
|
DNA Methylation | 1 | 2017 | 4286 | 0.060 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1061 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2703 | 0.060 |
Why?
|
Patient Discharge | 1 | 2016 | 3313 | 0.050 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 16689 | 0.050 |
Why?
|
Normetanephrine | 1 | 2021 | 26 | 0.050 |
Why?
|
Time Factors | 2 | 2021 | 40075 | 0.050 |
Why?
|
Adult | 12 | 2023 | 214055 | 0.050 |
Why?
|
Antipsychotic Agents | 1 | 2015 | 3057 | 0.050 |
Why?
|
Chromogranins | 1 | 2021 | 160 | 0.050 |
Why?
|
Survival Analysis | 2 | 2014 | 10252 | 0.050 |
Why?
|
Busulfan | 1 | 2021 | 263 | 0.050 |
Why?
|
Genotype | 4 | 2019 | 12951 | 0.050 |
Why?
|
Transplantation, Homologous | 2 | 2022 | 4776 | 0.050 |
Why?
|
Proportional Hazards Models | 2 | 2012 | 12354 | 0.050 |
Why?
|
United States | 4 | 2022 | 69872 | 0.040 |
Why?
|
Psychotic Disorders | 1 | 2015 | 3046 | 0.040 |
Why?
|
Polyethylene Glycols | 2 | 2020 | 1182 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2020 | 152 | 0.040 |
Why?
|
Risk Assessment | 1 | 2021 | 23338 | 0.040 |
Why?
|
Transcription Factors | 2 | 2024 | 12208 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7181 | 0.040 |
Why?
|
Prospective Studies | 2 | 2016 | 53288 | 0.040 |
Why?
|
Adrenal Glands | 1 | 2021 | 546 | 0.040 |
Why?
|
Aniline Compounds | 1 | 2023 | 986 | 0.040 |
Why?
|
Prevalence | 3 | 2010 | 15226 | 0.040 |
Why?
|
Nitriles | 1 | 2023 | 956 | 0.040 |
Why?
|
Asparaginase | 1 | 2020 | 236 | 0.040 |
Why?
|
Anemia, Aplastic | 1 | 2020 | 226 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7659 | 0.040 |
Why?
|
Vincristine | 1 | 2020 | 1039 | 0.040 |
Why?
|
Daunorubicin | 1 | 2017 | 158 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2009 | 3703 | 0.030 |
Why?
|
Benzylamines | 1 | 2017 | 223 | 0.030 |
Why?
|
Reference Standards | 1 | 2020 | 1025 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9648 | 0.030 |
Why?
|
Survival Rate | 2 | 2020 | 12788 | 0.030 |
Why?
|
Neoplasms | 3 | 2018 | 21683 | 0.030 |
Why?
|
Syndrome | 1 | 2021 | 3251 | 0.030 |
Why?
|
Hospitalization | 1 | 2015 | 10262 | 0.030 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2016 | 165 | 0.030 |
Why?
|
Benzothiazoles | 1 | 2016 | 248 | 0.030 |
Why?
|
Community Mental Health Centers | 1 | 2015 | 102 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2010 | 8428 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 4751 | 0.030 |
Why?
|
Chromosome Duplication | 1 | 2014 | 74 | 0.030 |
Why?
|
Transplantation | 1 | 2016 | 217 | 0.030 |
Why?
|
Ribavirin | 1 | 2016 | 395 | 0.030 |
Why?
|
DNA, Neoplasm | 2 | 2010 | 1758 | 0.030 |
Why?
|
Critical Pathways | 1 | 2018 | 476 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2018 | 1588 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2018 | 498 | 0.030 |
Why?
|
Pilot Projects | 2 | 2020 | 8324 | 0.030 |
Why?
|
Hematopoietic Stem Cells | 1 | 2006 | 3386 | 0.030 |
Why?
|
Whole-Body Irradiation | 1 | 2014 | 449 | 0.030 |
Why?
|
Doxorubicin | 1 | 2020 | 2234 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 2020 | 1151 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2020 | 1275 | 0.030 |
Why?
|
Bone Marrow | 2 | 2016 | 2948 | 0.030 |
Why?
|
Dexamethasone | 1 | 2020 | 1951 | 0.030 |
Why?
|
Proto-Oncogenes | 1 | 2013 | 321 | 0.030 |
Why?
|
Homozygote | 1 | 2017 | 1785 | 0.030 |
Why?
|
Administration, Oral | 1 | 2020 | 3913 | 0.030 |
Why?
|
Receptors, CXCR4 | 1 | 2017 | 726 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2016 | 652 | 0.020 |
Why?
|
Observer Variation | 1 | 2017 | 2593 | 0.020 |
Why?
|
DNA Mutational Analysis | 2 | 2010 | 4186 | 0.020 |
Why?
|
Heterozygote | 1 | 2017 | 2804 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2013 | 769 | 0.020 |
Why?
|
Siblings | 1 | 2014 | 854 | 0.020 |
Why?
|
Electronic Health Records | 2 | 2017 | 4468 | 0.020 |
Why?
|
Filgrastim | 1 | 2009 | 133 | 0.020 |
Why?
|
Acute Disease | 2 | 2010 | 7149 | 0.020 |
Why?
|
Outpatients | 1 | 2016 | 1486 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2010 | 17446 | 0.020 |
Why?
|
Karyotyping | 1 | 2010 | 1243 | 0.020 |
Why?
|
Clone Cells | 1 | 2011 | 1692 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2011 | 1880 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2011 | 1850 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39050 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5867 | 0.020 |
Why?
|
Neutrophils | 1 | 2018 | 3719 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2011 | 2649 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5952 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2017 | 3647 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2864 | 0.020 |
Why?
|
Bone Marrow Cells | 1 | 2011 | 2513 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2016 | 2987 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7799 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3749 | 0.010 |
Why?
|
Length of Stay | 1 | 2016 | 6309 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2009 | 3846 | 0.010 |
Why?
|
Patient Readmission | 1 | 2016 | 3114 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4149 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5172 | 0.010 |
Why?
|
Cohort Studies | 2 | 2016 | 40561 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13408 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6622 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 9959 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 19905 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23403 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2009 | 4328 | 0.010 |
Why?
|
Health Care Costs | 1 | 2009 | 3209 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 35421 | 0.010 |
Why?
|
Middle Aged | 1 | 2015 | 213383 | 0.000 |
Why?
|